Tactile Systems Technology, Inc. (NASDAQ:TCMD) on Tuesday posted upbeat fourth-quarter earnings and also announced the acquisition of LymphaTech.
Tactile Systems reported fourth-quarter earnings of 46 cents, better than the consensus of 44 cents. Sales jumped 21% to $103.59 million, beating the Wall Street estimates of $93.80 million, attributable to lymphedema and airway clearance product lines.
Tactile Systems forecasts fiscal 2026 sales between $357 million-$365 million compared to the consensus of $347.94 million. The company expects adjusted EBITDA in the range of $49 million to $51 million.
“In 2025, we executed with discipline against our core growth strategies, delivering double-digit revenue growth, expanding gross margin and adjusted EBITDA, and generating strong cash flow, while continuing to strategically invest in people and workflow-related processes to strengthen our business for scale,” said Sheri Dodd, Chief Executive Officer of Tactile Medical. “We delivered on our goals, and in doing so, advanced our mission of improving the lives of over 95,000 patients with lymphedema and chronic inflammatory lung disease.”
Tactile Systems shares fell 5.3% to close at $283.46 on Tuesday.
These analysts made changes to their price targets on Tactile Systems following earnings announcement.
- BTIG analyst Ryan Zimmerman maintained Tactile Systems Tech with a Buy and raised the price target from $36 to $38.
- Piper Sandler analyst Adam Maeder maintained the stock with an Overweight rating and raised the price target from $35 to $42.
Considering buying TCMD stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments